Pembrolizumab for untreated advanced Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called pembrolizumab as the first treatment for advanced-stage classical Hodgkin lymphoma. It may help shrink tumors and keep the disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have advanced-stage classical Hodgkin lymphoma (a type of lymphoma).
- You have not had any prior treatment for this lymphoma.
- You do not have a different type of Hodgkin lymphoma (like nodular lymphocyte-predominant).
- You have not had chemotherapy or radiation before.
- You have no other condition that would make this treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This study looks at how a type of immune cell aging (called 'immunological senescence') might affect how well the drug pembrolizumab works in people whose Hodgkin lymphoma has come back or not responded to treatment.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.